Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?
One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the global genome market is expected to expand at a compound annual growth rate of more than 16% until the end of the decade. Stocks involved in gene-editing therapies could be incredible investments to hold on to in the long run. One of them is CRISPR Therapeutics (NASDAQ: CRSP). It has an approved gene-editing therapy, but investors haven't been buying up the stock. Instead, it's been in a free fall over the past year. Its financials haven't been looking all that impressive and as a result, growth investors have been dumping the stock. But could that be a mistake?Image source: Getty Images.Continue reading
One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the global genome market is expected to expand at a compound annual growth rate of more than 16% until the end of the decade. Stocks involved in gene-editing therapies could be incredible investments to hold on to in the long run.
One of them is CRISPR Therapeutics (NASDAQ: CRSP). It has an approved gene-editing therapy, but investors haven't been buying up the stock. Instead, it's been in a free fall over the past year. Its financials haven't been looking all that impressive and as a result, growth investors have been dumping the stock. But could that be a mistake?
Image source: Getty Images.
